Brought to you by 
Genentech teams up with Kineta in chronic pain; deal later expanded
08 Oct 2020
Executive Summary
Kineta Inc.'s Kineta Chronic Pain LLC provided Roche's Genentech Inc. with an option on exclusive development and commercialization rights to its alpha 9/alpha 10 nicotinic acetylcholine receptor (nAChR) antagonists for chronic pain.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genentech teams up with Kineta in chronic pain; deal later expanded
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice